Freeline Therapeutics Holdings plc - ADR

NASDAQ:FRLN   3:59:53 PM EDT
1.37
-0.03 (-2.14%)
Layoffs, Other Pre-Announcement

Freeline Announces 2022 Corporate Priorities And Guidance

Published: 12/13/2021 22:52 GMT
Freeline Therapeutics Holdings plc - ADR (FRLN) - Freeline Announces 2022 Corporate Priorities and Guidance.
Freeline Therapeutics Holdings Plc - Expects to Incur Charges Relating to Its Proposed Workforce Reduction Between $2.1 and $2.6 Million in Q4 of 2021.
Freeline Therapeutics Holdings Plc - Data Anticipated Across All Programs by Mid-2022.
Freeline Therapeutics Holdings Plc - Expects Current Level of Cash and Cash Equivalents Will Enable Co to Fund Its Operating Expenses Into Q2 2023.
Freeline Therapeutics Holdings Plc - Proposed 25% Workforce Reduction.
Freeline Therapeutics Holdings Plc - Workforce Reduction Expected to Result in $1.3 Million to $1.6 Million of Cash Expenditures in Q1 of 2022.
Freeline Therapeutics Holdings Plc - Workforce Reduction Expected to Result in $0.8 Million to $1.0 Million of Cash Expenditures in Q2 of 2022.
Freeline Therapeutics - Estimates Proposed Reduction in Force to Decrease Aggregate Cash Expenditures by Between $4.7 Million and $5.1 Million in 2022.
Freeline Therapeutics - Estimates Proposed Reduction in Force to Decrease Aggregate Cash Expenditures by Between $7.0 Million and $7.6 Million in 2023.
Freeline Therapeutics - Expects Its Current Level of Cash and Cash Equivalents to Enable Co to Fund Operating Expenses Into Q2 2023.